NPI: 1396897203 · ROMNEY, WV 26757 · Critical Access Hospital · NPI assigned 01/18/2007
Authorized official CHAMBERS, JILL controls 20+ related entities in our dataset. Read more
| Authorized Official | CHAMBERS, JILL (MANAGER INSURANCE CREDENTIALING) |
| NPI Enumeration Date | 01/18/2007 |
Other providers sharing the same authorized official: CHAMBERS, JILL
| Year | Claims | Total Paid |
|---|---|---|
| 2018 | 26,062 | $2.28M |
| 2019 | 14,893 | $1.23M |
| 2020 | 24,940 | $2.00M |
| 2021 | 25,672 | $1.73M |
| 2022 | 11,417 | $698K |
| 2023 | 12,322 | $889K |
| 2024 | 9,233 | $762K |
| Code | Description | Claims | Beneficiaries | Total Paid |
|---|---|---|---|---|
| 99283 | Emergency department visit for the evaluation and management, moderate severity | 12,911 | 11,302 | $2.15M |
| 99285 | Emergency department visit for the evaluation and management, high severity with immediate threat to life | 5,763 | 3,887 | $1.81M |
| 99284 | Emergency department visit for the evaluation and management, high severity | 4,417 | 3,496 | $1.03M |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 428 | 403 | $361K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | 11,783 | 9,912 | $356K |
| 80053 | Comprehensive metabolic panel | 9,237 | 8,170 | $328K |
| 36415 | Collection of venous blood by venipuncture | 12,323 | 10,253 | $185K |
| 70450 | Computed tomography, head or brain; without contrast material | 636 | 602 | $178K |
| 96361 | Intravenous infusion, hydration; each additional hour | 1,988 | 1,651 | $177K |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | 1,872 | 1,722 | $175K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 1,231 | 1,142 | $163K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | 4,264 | 3,669 | $162K |
| 84443 | Thyroid stimulating hormone (TSH) | 3,325 | 3,186 | $142K |
| 71046 | Radiologic examination, chest; 2 views | 2,604 | 2,442 | $130K |
| 96375 | Therapeutic injection; each additional sequential IV push | 1,630 | 1,451 | $126K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | 1,044 | 884 | $120K |
| 81001 | 3,729 | 3,395 | $119K | |
| 80061 | Lipid panel | 2,556 | 2,467 | $116K |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | 2,087 | 670 | $108K |
| 80048 | Basic metabolic panel (calcium, ionized) | 2,911 | 2,473 | $100K |
| 84484 | 2,548 | 1,903 | $73K | |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | 1,392 | 1,119 | $70K |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | 120 | 114 | $69K |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | 1,970 | 947 | $65K |
| 87086 | Culture, bacterial; quantitative colony count, urine | 2,021 | 1,841 | $65K |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | 2,006 | 1,891 | $64K |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | 1,185 | 1,108 | $56K |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | 1,359 | 1,274 | $53K |
| 83036 | Hemoglobin; glycosylated (A1C) | 1,693 | 1,637 | $52K |
| 71045 | Radiologic examination, chest; single view | 1,522 | 1,378 | $48K |
| 77067 | Screening mammography, bilateral, including computer-aided detection | 222 | 217 | $47K |
| 87081 | 1,173 | 1,113 | $43K | |
| 83690 | 997 | 916 | $41K | |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | 683 | 658 | $41K |
| 0241U | Neonatal screening for hereditary disorders, genomic sequence analysis panel | 1,165 | 1,089 | $39K |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | 682 | 506 | $36K |
| 82948 | 1,402 | 303 | $34K | |
| 87186 | 916 | 788 | $32K | |
| 83880 | 626 | 549 | $29K | |
| 80306 | 524 | 487 | $28K | |
| 85610 | 1,470 | 1,034 | $28K | |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | 446 | 433 | $26K |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | 59 | 42 | $23K |
| 81025 | 440 | 415 | $21K | |
| 84439 | 600 | 575 | $21K | |
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | 380 | 123 | $20K |
| 85379 | 323 | 294 | $20K | |
| 94664 | 402 | 360 | $19K | |
| 82607 | 392 | 377 | $19K | |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | 165 | 156 | $18K |
| 96376 | 168 | 115 | $16K | |
| 87798 | Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism | 214 | 206 | $16K |
| 87070 | 182 | 154 | $16K | |
| 81003 | 754 | 712 | $16K | |
| 80076 | 341 | 315 | $15K | |
| 87077 | 361 | 303 | $15K | |
| 87040 | 202 | 164 | $15K | |
| 83735 | 662 | 549 | $12K | |
| 73564 | 198 | 184 | $12K | |
| 83605 | 305 | 255 | $11K | |
| 82746 | 228 | 217 | $11K | |
| 87634 | 355 | 343 | $10K | |
| 99211 | Office or other outpatient visit for the evaluation and management of an established patient, minimal severity | 561 | 349 | $10K |
| 84703 | 142 | 136 | $10K | |
| 73630 | 158 | 149 | $8K | |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | 127 | 112 | $7K |
| 84466 | 167 | 164 | $7K | |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | 86 | 76 | $7K |
| 76700 | Ultrasound, abdominal, real time with image documentation; complete | 27 | 26 | $6K |
| 72110 | 63 | 62 | $6K | |
| 87205 | 125 | 111 | $6K | |
| 94760 | 111 | 85 | $6K | |
| 82550 | 177 | 161 | $5K | |
| J7620 | Albuterol, up to 2.5 mg and ipratropium bromide, up to 0.5 mg, fda-approved final product, non-compounded, administered through dme | 163 | 130 | $5K |
| 92507 | Treatment of speech, language, voice, communication, and/or auditory processing disorder | 207 | 73 | $5K |
| 73030 | 116 | 108 | $5K | |
| 97161 | 57 | 54 | $5K | |
| S0119 | Ondansetron, oral, 4 mg (for circumstances falling under the medicare statute, use hcpcs q code) | 52 | 45 | $5K |
| G0378 | Hospital observation service, per hour | 28 | 28 | $5K |
| 73610 | 104 | 101 | $5K | |
| 83540 | 172 | 168 | $4K | |
| 87420 | 82 | 78 | $4K | |
| J7512 | Prednisone, immediate release or delayed release, oral, 1 mg | 110 | 98 | $4K |
| 97140 | Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) | 65 | 31 | $3K |
| 76536 | 26 | 25 | $3K | |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | 31 | 28 | $3K |
| 73130 | 72 | 63 | $3K | |
| 87426 | Infectious agent antigen detection, SARS-CoV-2 (COVID-19) | 146 | 132 | $3K |
| 11042 | Debridement, subcutaneous tissue (includes epidermis, dermis, and subcutaneous tissue); first 20 sq cm | 15 | 13 | $3K |
| 82570 | 106 | 101 | $3K | |
| 77063 | Screening digital breast tomosynthesis, bilateral | 62 | 61 | $2K |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | 108 | 94 | $2K |
| 86140 | 235 | 207 | $2K | |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | 25 | 13 | $2K |
| 12001 | 17 | 12 | $2K | |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | 27 | 27 | $2K |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | 27 | 27 | $2K |
| 85651 | 50 | 47 | $2K | |
| 93010 | Electrocardiogram, routine ECG with at least 12 leads; interpretation and report only | 346 | 304 | $2K |
| 82728 | 40 | 40 | $1K | |
| 73110 | 32 | 28 | $1K | |
| 82043 | 54 | 53 | $1K | |
| 97597 | 14 | 12 | $1K | |
| 82803 | 34 | 26 | $1K | |
| 73502 | 24 | 24 | $1K | |
| J7613 | Albuterol, inhalation solution, fda-approved final product, non-compounded, administered through dme, unit dose, 1 mg | 15 | 13 | $902.00 |
| 72040 | 13 | 12 | $636.64 | |
| 72100 | 13 | 12 | $594.03 | |
| 82565 | 28 | 24 | $586.62 | |
| 85652 | 66 | 66 | $579.93 | |
| 87428 | 12 | 12 | $430.19 | |
| 82947 | 55 | 15 | $382.29 | |
| 36600 | 17 | 13 | $281.73 | |
| 85730 | 12 | 12 | $245.78 | |
| 84145 | 13 | 12 | $63.22 | |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | 43 | 41 | $60.68 |
| J3490 | Unclassified drugs | 31 | 25 | $44.86 |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | 29 | 28 | $29.83 |
| J8540 | Dexamethasone, oral, 0.25 mg | 15 | 15 | $3.58 |
| G1004 | Clinical decision support mechanism national decision support company, as defined by the medicare appropriate use criteria program | 194 | 159 | $0.01 |